PUBLISHER: Grand View Research | PRODUCT CODE: 1611242
PUBLISHER: Grand View Research | PRODUCT CODE: 1611242
U.S. Women's Health Market Size, Share & Trends Analysis Report By Application (Postmenopausal Osteoporosis, Infertility, Contraceptives, Menopause, PCOS), By Age, By Drug Class, And Segment Forecasts, 2025 - 2030
U.S. Women's Health Market Growth & Trends:
The U.S. women's health market size is estimated to reach USD 24.36 billion by 2030, expanding at a CAGR of 3.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of target diseases is a key driver for the growth of the market. With aging and the increasing prevalence of obesity, the prevalence of osteoarthritis is anticipated to grow. Some of the major factors responsible for hormonal imbalance in women include changes in dietary habits, stress, and consumption of alcohol, which can cause fertility issues. Ovulation problems, polycystic ovarian syndrome (PCOS), and endometriosis are major factors responsible for infertility.
The rise in public funding for family planning services is further driving the market growth. In the U.S., approximately 45% of pregnancies are estimated to be unwanted every year. Despite advancements in contraceptive technology and increased R&D spending on contraceptives, the rate of unplanned pregnancies in the U.S. has remained unchanged for decades. This has increased the economic burden on low-income families that do not have easy access to modern and more effective methods of contraception. Hence, federal & state governments are actively working toward improving family planning services and access to modern contraceptives. For instance, in 2019, the U.S. government provided USD 608 million in funding to UNFPA for family planning & reproductive health development.
Moreover, child marriages are most common in underdeveloped and developing economies, often leading to early and unplanned pregnancies. There is a lack of awareness about contraceptives, which amplifies the severity of the problem. According to UNICEF, child marriages decreased by 15% in the past decade. However, the number has not decreased over the years in the U.S. because laws in certain U.S. states allow marriages before 18 years. However, efforts to address child marriage and its impact on women's health are being undertaken in the country, which involve advocating for policy changes, promoting girls' education, raising awareness about the negative consequences of child marriage, and providing support services for affected girls and women.
Furthermore, key players involved in developing and formulating various therapeutics are focusing on collaborations and partnerships to develop novel drugs and maintain their competitive position in the market. For instance, in October 2022, Solera Health announced the launch of first-of-its-kind digital point solutions for women's Health networks to address women's health issues needs. Moreover, in November 2022, Sebela Pharmaceuticals announced the launch of a new division fully dedicated to women's health.
U.S. Women's Health Market Report Highlights:
- Based on drug, the Prolia drug segment held the largest revenue share in 2024 and is anticipated to grow at the fastest CAGR over the forecast period owing to the wide adoption of the drug with very less side effects
- Based on application, the contraceptives segment is expected to showcase the fastest CAGR over the forecast period, owing to an increase in awareness about family planning
- Based on age, the others age segment dominated the U.S. women's health industry in 2024, due to the rising concerns of fertility, such as endometriosis, hormonal infertility, and PCOS in this age group
- Based on distribution channel, the hospital pharmacy segment dominated the market in 2024 due to the high stock and availability of women's health therapeutics in the hospital pharmacies
- Key market players are constantly focusing on product launches and geographical expansion to maintain their presence
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Application
- 1.2.2. Age
- 1.2.3. Drug
- 1.2.4. Estimates and forecasts timeline.
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database.
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in U.S.
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Application outlook
- 2.2.2. Age outlook
- 2.2.3. Drug outlook.
- 2.3. Competitive Insights
Chapter 3. U.S. Women's Health Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Rising incidence of target diseases
- 3.2.1.2. Increasing initiatives by government and various organizations
- 3.2.1.3. Rising publicly funded family planning services
- 3.2.2. Market restraint analysis
- 3.2.2.1. Patent expiry of major drugs
- 3.2.2.2. Lawsuits related to products.
- 3.2.2.3. Adverse effects associated with use of contraceptive drugs and devices.
- 3.2.1. Market driver analysis
- 3.3. U.S. Women's Health Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.3. Pricing Analysis
- 3.3.1. Industry Analysis - Porter's
Chapter 4. U.S. Women's Health Market: Application Estimates & Trend Analysis
- 4.1. Application Market Share, 2023 & 2030
- 4.2. Segment Dashboard
- 4.3. U.S. Women's Health Market by Application Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.4.1. Hormonal infertility
- 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.2. Contraceptives
- 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.3. Postmenopausal osteoporosis
- 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.4. Endometriosis & uterine fibroids
- 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.5. Menopause
- 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.6. Polycystic ovary syndrome (PCOS)
- 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.1. Hormonal infertility
Chapter 5. U.S. Women's Health Market: Drug Class Estimates & Trend Analysis
- 5.1. Drug Class Market Share, 2023 & 2030
- 5.2. Segment Dashboard
- 5.3. U.S. Women's Health Market by Drug Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.4.1. Hormonal Therapies
- 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.2. Bone Health Agents
- 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.3. Fertility Agents
- 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.4. GnRH Modulators
- 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.5. Pain and Symptom Management
- 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.6. Metabolic Agents
- 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.7. Others
- 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.1. Hormonal Therapies
Chapter 6. U.S. Women's Health Market: Age Estimates & Trend Analysis
- 6.1. Age Market Share, 2023 & 2030
- 6.2. Segment Dashboard
- 6.3. U.S. Women's Health Market by Age Outlook
- 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.4.1. 50 years and above
- 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.1.2. Postmenopausal osteoporosis
- 6.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.1.3. Endometriosis & uterine fibroids
- 6.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.1.4. Menopause
- 6.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.1.5. Others
- 6.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.2. Others
- 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.1. 50 years and above
Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Company/Competition Categorization
- 7.3. Vendor Landscape
- 7.3.1. List of key distributors and channel partners
- 7.3.2. Key customers
- 7.3.3. Key company market share analysis, 2024
- 7.3.4. AbbVie, Inc.
- 7.3.4.1. Company overview
- 7.3.4.2. Financial performance
- 7.3.4.3. Product benchmarking
- 7.3.4.4. Strategic initiatives
- 7.3.5. Bayer AG
- 7.3.5.1. Company overview
- 7.3.5.2. Financial performance
- 7.3.5.3. Product benchmarking
- 7.3.5.4. Strategic initiatives
- 7.3.6. Merck & Co., Inc.
- 7.3.6.1. Company overview
- 7.3.6.2. Financial performance
- 7.3.6.3. Product benchmarking
- 7.3.6.4. Strategic initiatives
- 7.3.7. Pfizer, Inc.
- 7.3.7.1. Company overview
- 7.3.7.2. Financial performance
- 7.3.7.3. Product benchmarking
- 7.3.7.4. Strategic initiatives
- 7.3.8. Teva Pharmaceutical Industries Ltd.
- 7.3.8.1. Company overview
- 7.3.8.2. Financial performance
- 7.3.8.3. Product benchmarking
- 7.3.8.4. Strategic initiatives
- 7.3.9. Agile Therapeutics
- 7.3.9.1. Company overview
- 7.3.9.2. Financial performance
- 7.3.9.3. Product benchmarking
- 7.3.9.4. Strategic initiatives
- 7.3.10. Amgen, Inc.
- 7.3.10.1. Company overview
- 7.3.10.2. Financial performance
- 7.3.10.3. Product benchmarking
- 7.3.10.4. Strategic initiatives
- 7.3.11. Apothecus Pharmaceutical Corp.
- 7.3.11.1. Company overview
- 7.3.11.2. Financial performance
- 7.3.11.3. Product benchmarking
- 7.3.11.4. Strategic initiatives
- 7.3.12. Eli Lilly and Company
- 7.3.12.1. Company overview
- 7.3.12.2. Financial performance
- 7.3.12.3. Product benchmarking
- 7.3.12.4. Strategic initiatives
- 7.3.13. Ferring B.V.
- 7.3.13.1. Company overview
- 7.3.13.2. Financial performance
- 7.3.13.3. Product benchmarking
- 7.3.13.4. Strategic initiatives
List of Tables
- Table 1 List of abbreviation
- Table 2 U.S. Women's Health Market, by application, 2018 - 2030 (USD Million)
- Table 3 U.S. Women's Health Market, by drug class, 2018 - 2030 (USD Million)
- Table 4 U.S. Women's Health Market, by age, 2018 - 2030 (USD Million)
List of Figures
- Fig. 1 Market research process
- Fig. 2 Data triangulation techniques
- Fig. 3 Primary research pattern
- Fig. 4 Primary interviews in U.S.
- Fig. 5 Market research approaches
- Fig. 6 Value-chain-based sizing & forecasting
- Fig. 7 QFD modeling for market share assessment
- Fig. 8 Market formulation & validation
- Fig. 9 U.S. Women's Health Market: market outlook
- Fig. 10 Women's health competitive insights
- Fig. 11 Parent market outlook
- Fig. 12 Related/ancillary market outlook
- Fig. 13 Penetration and growth prospect mapping
- Fig. 14 Industry value chain analysis
- Fig. 15 U.S. Women's Health Market driver impact
- Fig. 16 U.S. Women's Health Market restraint impact
- Fig. 17 U.S. Women's Health Market strategic initiatives analysis
- Fig. 18 U.S. Women's Health Market: Application movement analysis
- Fig. 19 U.S. Women's Health Market: Application outlook and key takeaways
- Fig. 20 Hormonal infertility market estimates and forecast, 2018 - 2030
- Fig. 21 Contraceptives estimates and forecast, 2018 - 2030
- Fig. 22 Postmenopausal osteoporosis market estimates and forecast, 2018 - 2030
- Fig. 23 Endometriosis & uterine fibroids estimates and forecast, 2018 - 2030
- Fig. 24 Menopause market estimates and forecast, 2018 - 2030
- Fig. 25 Polycystic ovary syndrome (PCOS) estimates and forecast, 2018 - 2030
- Fig. 26 U.S. Women's Health Market: Drug movement analysis
- Fig. 27 U.S. Women's Health Market: Drug outlook and key takeaways
- Fig. 28 Hormonal Therapies market estimates and forecast, 2018 - 2030
- Fig. 29 Bone Health Agents estimates and forecast, 2018 - 2030
- Fig. 30 Fertility Agents market estimates and forecast, 2018 - 2030
- Fig. 31 GnRH Modulators estimates and forecast, 2018 - 2030
- Fig. 32 Metabolic Agents market estimates and forecast, 2018 - 2030
- Fig. 33 Pain and Symptom Management estimates and forecast, 2018 - 2030
- Fig. 34 Others estimates and forecast, 2018 - 2030
- Fig. 35 U.S. Women's Health Market: Age movement Analysis
- Fig. 36 U.S. Women's Health Market: Age outlook and key takeaways
- Fig. 37 50 years and above market estimates and forecasts, 2018 - 2030
- Fig. 38 Postmenopausal osteoporosis market estimates and forecasts, 2018 - 2030
- Fig. 39 Endometriosis & uterine fibroids market estimates and forecasts, 2018 - 2030
- Fig. 40 Menopause market estimates and forecasts, 2018 - 2030
- Fig. 41 Others market estimates and forecasts, 2018 - 2030
- Fig. 42 Others market estimates and forecasts, 2018 - 2030
- Fig. 43 Market share of key market players- U.S. Women's Health Market
